Previous 10 | Next 10 |
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor The...
CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced the appointment of Patrick Wen, M.D., an accomplished neu...
August 27, 2020 Palm Beach, FL – August 27, 2020 – Across the globe, there has been an increasing prevalence on brain cancer over the past few years and the industry is expected to grow as a result. The major driving factor responsible for the growth of brain tumors ...
HOUSTON , Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces Pa...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced its engagement of Worldwide Clinical Trials as the contract research organization (...
CNS Pharmaceuticals (NASDAQ: CNSP ) is making strides in designing Phase 2 clinical trials fro Berubicin and anticipates submitting an Investigational New Drug application (IND) to the FDA this year and initiating clinical trials in early 2021. More news on: CNS Pharmaceuticals, Inc....
HOUSTON , Aug. 25, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an u...
Gainers: Cancer Genetics (NASDAQ: CGIX ) +142% . More news on: Cancer Genetics, Inc., iBio, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...
August 20, 2020 Palm Beach, FL – August 20, 2020 – Various reports on the global metastatic cancer treatment market all project continued growth in the next several years. One such report from Industry Research says that the global metastatic cancer treatment market ...
HOUSTON , Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it ...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...